Nevertheless, RA therapeutics inhibiting pathogenetic pro-inflammatory cytokines like tumor necrosis factor (TNF) and interleukin-6 (IL-6) alleviate symptoms such as depression and anxiety (17, 18) and were linked to a reduced risk of future neurodegeneration (19) in RA patients. This evidence concerns the gene IL6 and depressive symptom measurement.